Acorda Therapeutics (STU:CDG) EPS Growth Rate (Future 3Y To 5Y Estimate) : 46.00 (As of May. 24, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Acorda Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Acorda Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) is 46.00.

Competitive Comparison of Acorda Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acorda Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Acorda Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Acorda Therapeutics (STU:CDG) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Acorda Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Acorda Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Acorda Therapeutics (STU:CDG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (STU:CDG) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

ACOR:USA

Address

2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965

Website

https://www.acorda.com

Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Acorda Therapeutics (STU:CDG) Headlines

No Headlines